Evidence map›Paper›PMID 33785830›Full record

SynthesisScientific reports2021

A systematic review and meta-analysis of obesity and COVID-19 outcomes.

Xinya Zhang, Alexander M Lewis, John R Moley, Jonathan R Brestoff

Open access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 3 pooled it
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 3 syntheses or guidelines pooled it, 92 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Xinya Zhang *Department of Pathology and Immunology, Washington University School of Medicine, Mail: 660 S. Euclid Ave - Campus Box 8118, Lab: 425 S. Euclid Ave - 3710 West Building, St. Louis, MO, 63110, USA.
Alexander M Lewis *Skidmore College, Saratoga Springs, NY, USA.
John R Moley *Department of Pathology and Immunology, Washington University School of Medicine, Mail: 660 S. Euclid Ave - Campus Box 8118, Lab: 425 S. Euclid Ave - 3710 West Building, St. Louis, MO, 63110, USA.
Jonathan R BrestoffDepartment of Pathology and Immunology, Washington University School of Medicine, Mail: 660 S. Euclid Ave - Campus Box 8118, Lab: 425 S. Euclid Ave - 3710 West Building, St. Louis, MO, 63110, USA. brestoff@wustl.edu.
Skidmore College · USWashington University in St. Louis · US

Funding

Regulation of innate immune cell responses through cell-to-cell transfer of mitochondriaDP5OD028125 · OD · WASHINGTON UNIVERSITY · PI BRESTOFF, JONATHAN R · 2019 to 2023
$2.0M
Burroughs Wellcome Fund CAMS 1019648NIH HHS DP5 OD028125ODCDC CDC HHS DP5 OD028125
6 · The paper itself

Abstract

Some studies report that obesity is associated with more severe symptoms following SARS-CoV-2 infection and worse COVID-19 outcomes, however many other studies have not reproduced these findings. Therefore, it is uncertain whether obesity is in fact associated with worse COVID-19 outcomes compared to non-obese individuals. We conducted a systematic search of PubMed (including MEDLINE) and Google Scholar on May 18, 2020 to identify published studies on COVID-19 outcomes in non-obese and obese patients, covering studies published during the first 6 months of the pandemic. Meta-analyses with random effects modeling was used to determine unadjusted odds ratios (OR) and 95% confidence intervals (CI) for various COVID-19 outcomes in obese versus non-obese patients. By quantitative analyses of 22 studies from 7 countries in North America, Europe, and Asia, we found that obesity is associated with an increased likelihood of presenting with more severe COVID-19 symptoms (OR 3.03, 95% CI 1.45-6.28, P = 0.003; 4 studies, n = 974), developing acute respiratory distress syndrome (ARDS; OR 2.89, 95% CI 1.14-7.34, P = 0.025; 2 studies, n = 96), requiring hospitalization (OR 1.68, 95% CI 1.14-1.59, P < 0.001; 4 studies, n = 6611), being admitted to an intensive care unit (ICU; OR 1.35, 95% CI 1.15-1.65, P = 0.001; 9 studies, n = 5298), and undergoing invasive mechanical ventilation (IMV; OR 1.76, 95% CI 1.29-2.40, P < 0.001; 7 studies, n = 1558) compared to non-obese patients. However, obese patients had similar likelihoods of death from COVID-19 as non-obese patients (OR 0.96, 95% CI 0.74-1.25, P = 0.750; 9 studies, n = 20,597). Collectively, these data from the first 6 months of the pandemic suggested that obesity is associated with a more severe COVID-19 disease course but may not be associated with increased mortality.

Indexed as

AsiaComorbidityCOVID-19EuropeHospitalizationHumansIntensive Care UnitsMortalityNorth AmericaObesityOdds RatioRespiration, ArtificialRespiratory Distress Syndrome

Identifiers

PMID33785830
PMCPMC8009961
OpenAlexW3145857755

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.